Page last updated: 2024-08-24

sdz 208-912 and opc 4392

sdz 208-912 has been researched along with opc 4392 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bailey, P; Castro, JO; Crocq, MA; Duval, F; Lataste, X; Macher, JP; Mokrani, MC1
Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y1

Trials

1 trial(s) available for sdz 208-912 and opc 4392

ArticleYear
Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.
    Psychopharmacology, 1993, Volume: 110, Issue:1-2

    Topics: Adult; Amisulpride; Antipsychotic Agents; Apomorphine; Dopamine Agonists; Ergolines; Female; Growth Hormone; Humans; Male; Neurosecretory Systems; Piperazines; Prolactin; Quinolones; Schizophrenia; Sulpiride

1993

Other Studies

1 other study(ies) available for sdz 208-912 and opc 4392

ArticleYear
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
    European journal of pharmacology, 2007, Nov-28, Volume: 574, Issue:2-3

    Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia

2007